A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer

Overview of attention for article published in Journal of Immunotherapy, February 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 85 Dimensions

Readers on

mendeley: 92 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 85 publications that cite this research output.

85

The most recent citing publications are shown below. View all 85 publications that cite this research output on Dimensions.

Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Article in Journal for ImmunoTherapy of Cancer (January 2024)

Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment

Article in Vaccines (August 2023)

Adoptive cell therapy for cancer treatment

Article in Exploration (July 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.